1
|
Borson-Chazot F, Buffet C, Decaussin-Petrucci M, Cao CD, Drui D, Leboulleux S, Leenhardt L, Menegaux F, Pattou F, Lussey-Lepoutre C. SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules: Synthesis and algorithms. Ann Endocrinol (Paris) 2022; 83:440-453. [PMID: 36336101 DOI: 10.1016/j.ando.2022.11.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid with benign and non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment. The diagnosis and treatment of thyroid nodules requires close collaboration between endocrinologists, nuclear medicine physicians and surgeons but also involves other specialists. Therefore, this consensus statement was established jointly by 3 societies, the French Society of Endocrinology (SFE), the French Association of Endocrine Surgery (AFCE) and the French Society of Nuclear Medicine (SFMN); the various working groups included experts from other specialties (pathologists, radiologists, pediatricians, biologists, etc.). This specific text is a summary chapter taking up the recommendations from specific sections and presenting algorithms for the exploration and management of thyroid nodules.
Collapse
Affiliation(s)
- F Borson-Chazot
- Fédération d'endocrinologie, groupement hospitalier Est, hospices civils de Lyon, Lyon, France; Inserm U1290, université Claude-Bernard Lyon 1, Lyon, France.
| | - C Buffet
- Thyroid and Endocrine Tumors Department, Institute of Endocrinology, Pitié-Salpêtrière Hospital, AP-HP, 75013 Paris, France; Institute of Cancer IUC Sorbonne University GRC No. 16, 75013 Paris, France
| | - M Decaussin-Petrucci
- Pathology Department, centre hospitalier Lyon Sud, hospices civils de Lyon, Pierre-Bénite, France; EA 3738, Lyon 1 University, Lyon, France
| | - C Do Cao
- Department of Endocrinology, Diabetology and Metabolism, CHU de Lille, Lille, France
| | - D Drui
- Service d'endocrinologie-diabétologie et nutrition, l'institut du thorax, CHU de Nantes, Nantes Université, 44000 Nantes, France
| | - S Leboulleux
- Thyroid and Endocrine Tumors Department, Institute of Endocrinology, Pitié-Salpêtrière Hospital, AP-HP, 75013 Paris, France; Service d'endocrinologie, hôpitaux universitaires de Genève, 4, rue Gabrielle-Perret-Gentil, 1205 Genève, Switzerland
| | - L Leenhardt
- Institute of Cancer IUC Sorbonne University GRC No. 16, 75013 Paris, France
| | - F Menegaux
- Service de chirurgie endocrinienne, hôpital de la pitié Salpetrière, AP-HP, 75013 Paris, France
| | - F Pattou
- Inserm, service de chirurgie générale et endocrinienne, EGID, U1190, Lille Pasteur Institute, CHU de Lille, université Lille, Lille, France
| | - C Lussey-Lepoutre
- Inserm U970, service de médecine nucléaire, Sorbonne université, hôpital Pitié-Salpêtrière, AP-HP, Paris, France
| |
Collapse
|
2
|
Decaussin-Petrucci M, Albarel F, Leteurtre E, Borson-Chazot F, Cochand Priollet B. SFE-AFCE-SFMN 2022 Consensus on the management of thyroid nodules : Recommendations in thyroid cytology: from technique to interpretation. Ann Endocrinol (Paris) 2022; 83:389-394. [PMID: 36283459 DOI: 10.1016/j.ando.2022.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid, with benign non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment. The diagnosis and treatment of thyroid nodules requires close collaboration between endocrinologists, nuclear medicine physicians and surgeons, but also involves other specialists. Therefore, this consensus statement was established jointly by 3 societies: the French Society of Endocrinology (SFE), French Association of Endocrine Surgery (AFCE) and French Society of Nuclear Medicine (SFMN); the various working groups included experts from other specialties (pathologists, radiologists, pediatricians, biologists, etc.). This section deals with the technique and interpretation of thyroid fine-needle aspiration biopsy (FNAB), a reference test for the analysis of thyroid nodules.
Collapse
Affiliation(s)
- M Decaussin-Petrucci
- Pathology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France, EA 3738, Lyon 1 University, Lyon, France.
| | - F Albarel
- Service d'Endocrinologie, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Conception, Centre de Référence des Maladies Rares de l'Hypophyse HYPO, 13005 Marseille, France
| | - E Leteurtre
- University Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000 Lille, France
| | - F Borson-Chazot
- Fédération d'Endocrinologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France; Université Lyon 1, Claude Bernard, Lyon, France
| | - B Cochand Priollet
- Hôpital Cochin, Paris 75014, France; APHP Centre; université Paris-Cité, Paris, France
| |
Collapse
|
3
|
Decaussin-Petrucci M, Descotes F, Depaepe L, Lapras V, Denier ML, Borson-Chazot F, Lifante JC, Lopez J. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy. Cytopathology 2017; 28:482-487. [PMID: 29094776 DOI: 10.1111/cyt.12493] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/27/2017] [Indexed: 12/18/2022]
Abstract
OBJECTIVE Liquid-based (LB)-FNA is widely recognized as a reliable diagnostic method to evaluate thyroid nodules. However, up to 30% of LB-FNA remain indeterminate according to the Bethesda system. Use of molecular biomarkers has been recommended to improve its pathological accuracy but implementation of these tests in clinical practice may be difficult. Here, we evaluated feasibility and performance of molecular profiling in routine practice by testing LB-FNA for BRAF, N/HRAS and TERT mutations. METHODS We studied a large prospective cohort of 326 cases, including 61 atypia of undetermined significance, 124 follicular neoplasms, 72 suspicious for malignancy and 69 malignant cases. Diagnosis of malignancy was confirmed by histology on paired surgical specimen. RESULTS Mutated LB-FNAs were significantly associated with malignancy regardless of the cytological classification. Overall sensitivity was 60% and specificity 89%. Importantly, in atypia of undetermined significance and follicular neoplasm patients undergoing surgery according to the Bethesda guidelines, negative predictive values were 85.4% and 90% respectively. TERT promoter mutation was rare but very specific for malignancy (5.5%) suggesting that it could be of interest in patients with indeterminate cytology. CONCLUSIONS Mutation profiling can be successfully performed on thyroid LB-FNA without any dedicated sample in a pathology laboratory. It is an easy way to improve diagnostic accuracy of routine LB-FNA and may help to better select patients for surgery and to avoid unnecessary thyroidectomies.
Collapse
Affiliation(s)
- M Decaussin-Petrucci
- Pathology department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.,Cancer Research Center of Lyon, INSERM1052 CNRS5286, Université de Lyon, Lyon, France
| | - F Descotes
- Biochemistry and molecular biology department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - L Depaepe
- Pathology department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - V Lapras
- Radiology department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - M-L Denier
- Radiology department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - F Borson-Chazot
- Endocrinology department, Groupement hospitalier Est, Hospices Civils de Lyon, Bron, France
| | - J-C Lifante
- Endocrine surgery department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France
| | - J Lopez
- Biochemistry and molecular biology department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.,Cancer Research Center of Lyon, INSERM1052 CNRS5286, Université de Lyon, Lyon, France
| |
Collapse
|
4
|
Capraru O, Decaussin-Petrucci M, Joly M, Borda A, Fanfaret I, Borson-Chazot F, Selmi-Ruby S. EXPRESSION OF MENIN IN THE HUMAN THYROID GLAND. Acta Endocrinol (Buchar) 2017; 13:154-160. [PMID: 31149167 PMCID: PMC6516441 DOI: 10.4183/aeb.2017.154] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
INTRODUCTION The expression of menin in the thyroid gland has long been debated. Animal models with targeted inactivation of menin in the thyroid gland have shown that its inactivation might play a role in the progression to a more aggressive type of cancer. Human studies are conflicting, some have identified mutations in the MEN1 gene in a sub-type of oncocytic thyroid carcinomas, while others have not identified a higher prevalence of thyroid cancer in MEN1 patients. OBJECTIVE To analyze the immunohistochemical expression of menin in different types of thyroid carcinomas. MATERIALS AND METHODS 48 thyroid tumours (12 papillary thyroid carcinomas (PTC), 6 anaplastic thyroid carcinomas (ATC), 12 poorly differentiated thyroid carcinomas (PDTC), 5 medullary thyroid carcinomas (MTC), 5 oncocytic follicular carcinomas (OC), 3 oncocytic adenomas (OA) and 5 goiters (G)) were tested for nuclear expression of menin using an anti-menin antibody. The expression was considered positive, negative or decreased. RESULTS The expression of menin was positive, identical to normal tissue, in 39 cases (81.25%). The expression was decreased (n=8) or absent (n=1) in 9 tumours (18.75% - 2 PTC, 5 PDTC, 2 OC) accounting for 42% (5/12) of the PDTC and 40% (2/5) of the OC. CONCLUSIONS Our results show that the expression of menin is generally preserved in human thyroid carcinomas, but it can be decreased or absent in certain types of thyroid cancer. Further molecular studies are needed to evaluate to potential of menin protein in tumorigenesis.
Collapse
Affiliation(s)
- O.M. Capraru
- University of Medicine and Pharmacy Targu Mures, Dept. of Physiology, Targu Mures, Romania
- Université Claude Bernard Lyon 1 - INSERM Unité 1052, Centre de recherche en cancérologie, Lyon, France
| | - M. Decaussin-Petrucci
- Centre Hospitalier Lyon Sud, Pierre-Bénite, Hospices Civils de Lyon, Université Lyon 1 - Service d’Anatomie et Cytologie Pathologiques, Lyon, France
| | - M.O. Joly
- Hôpital Edouard Herriot, Hospices Civils de Lyon, Université Lyon 1 - Service d’Anatomie et Cytologie Pathologiques, Lyon, France
| | - A. Borda
- University of Medicine and Pharmacy Targu Mures, Dept. of Histology, Targu Mures, Romania
| | - I.S. Fanfaret
- University of Medicine and Pharmacy Targu Mures, Dept. of Histology, Targu Mures, Romania
| | - F. Borson-Chazot
- Université Claude Bernard Lyon 1 - INSERM Unité 1052, Centre de recherche en cancérologie, Lyon, France
- Groupement hospitalier Est, Bron, Hospices Civils de Lyon, Université Lyon 1 - Fédération d’endocrinologie, Lyon, France
| | - S. Selmi-Ruby
- Université Claude Bernard Lyon 1 - INSERM Unité 1052, Centre de recherche en cancérologie, Lyon, France
| |
Collapse
|
5
|
Rouviere O, Puech P, Renard Penna R, Claudon M, Roy C, Mege Lechevallier F, Decaussin-Petrucci M, Rabilloud M, Schott Pethelaz A, Dubreuil Chambardel M, Magaud L, Cros F, Barry Delongchamps N, Boutier R, Bratan F, Brunelle S, Camparo P, Colin P, Correas J, Cornélis F, Cornud F, Descotes J, Eschwege P, Fiard G, Fendler J, Habchi H, Hallouin P, Khairoune A, Lang H, Lebras Y, Malavaud B, Moldovan P, Mottet N, Mozer P, Nevoux P, Pagnoux G, Pasticier G, Portalez D, Potiron E, Timsit MO, Villers A, Walz J, Colombel M, Ruffion A, Crouzet S, Lemaitre L, Grenier N. Added value of pre-biopsy prostate multiparametric MRI in biopsy-naïve patients: Preliminary results of the MRI-FIRST trial. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/s1569-9056(17)30558-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
6
|
Vlaeminck-Guillem V, Devonec M, Champetier D, Decaussin-Petrucci M, Paparel P, Perrin P, Ruffion A. Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients. Prog Urol 2015. [DOI: 10.1016/j.purol.2015.10.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
7
|
Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J, Allioli N. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene 2014; 34:2846-55. [PMID: 25065599 DOI: 10.1038/onc.2014.222] [Citation(s) in RCA: 93] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Revised: 06/12/2014] [Accepted: 06/15/2014] [Indexed: 12/20/2022]
Abstract
Androgen signaling, via the androgen receptor (AR), is crucial in mediating prostate cancer (PCa) initiation and progression. Identifying new downstream effectors of the androgens/AR pathway will allow a better understanding of these mechanisms and could reveal novel biomarkers and/or therapeutic agents to improve the rate of patient survival. We compared the microRNA expression profiles in androgen-sensitive LNCaP cells stimulated or not with 1 nM R1881 by performing a high-throughput reverse transcriptase-quantitative PCR and found that miR-135a was upregulated. After androgen stimulation, we showed that AR directly activates the transcription of miR-135a2 gene by binding to an androgen response element in the promoter region. Our findings identify miR-135a as a novel effector in androgens/AR signaling. Using xenograft experiments in chick embryos and adult male mice, we showed that miR-135a overexpression decreases in vivo invasion abilities of prostate PC-3 cells. Through in vitro wound-healing migration and invasion assays, we demonstrated that this effect is mediated through downregulating ROCK1 and ROCK2 expression, two genes that we characterized as miR-135a direct target genes. In human surgical samples from prostatectomy, we observed that miR-135a expression was lower in tumoral compared with paired adjacent normal tissues, mainly in tumors classified with a high Gleason score (⩾8). Moreover, miR-135a expression is lower in invasive tumors, showing extraprostatic extension, as compared with intraprostatic localized tumors. In tumor relative to normal glands, we also showed a more frequently higher ROCK1 protein expression determined using a semi-quantitative immunohistochemistry analysis. Therefore, in tumor cells, the lower miR-135a expression could lead to a higher ROCK1 protein expression, which could explain their invasion abilities. The highlighted relationship between miR-135a expression level and the degree of disease aggressiveness suggests that miR-135a may be considered as a prognostic marker in human PCa.
Collapse
Affiliation(s)
- A Kroiss
- Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France
| | - S Vincent
- Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France
| | - M Decaussin-Petrucci
- 1] Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France [2] Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, Pierre-Bénite, France [3] Service d'Anatomie et de Cytologie Pathologiques, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - E Meugnier
- Laboratoire CarMen, INSERM U1060, INRA1362, Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Oullins, France
| | - J Viallet
- In Ovo, Institut Albert Bonniot, CRI INSERM/UJF U823, Université de Grenoble, La Tronche Cedex, France
| | - A Ruffion
- 1] Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France [2] Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, Pierre-Bénite, France [3] Service d'Urologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - F Chalmel
- GERHM, INSERM U1085-Irset, Université Rennes 1, Rennes, France
| | - J Samarut
- 1] Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France [2] Faculté de Médecine et de Maïeutique Lyon-Sud-Charles Mérieux, Université Claude Bernard Lyon 1, Pierre-Bénite, France [3] Service de Biochimie Biologie Moleculaire Sud, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France
| | - N Allioli
- 1] Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Institut de Génomique Fonctionnelle de Lyon (IGFL), Lyon, France [2] Institut des Sciences Pharmaceutiques et Biologiques (ISPB)-Faculté de Pharmacie de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| |
Collapse
|
8
|
Advenier AS, Casalegno JS, Mekki Y, Decaussin-Petrucci M, Mège-Lechevallier F, Ruffion A, Piaton E. Genotyping of high-risk human papillomaviruses in p16/Ki-67-positive urothelial carcinoma cells: even a worm will turn. Cytopathology 2014; 26:106-13. [PMID: 24785530 DOI: 10.1111/cyt.12150] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/24/2014] [Indexed: 12/25/2022]
Abstract
OBJECTIVE Co-expression of p16INK4a protein and Ki-67 (p16/Ki-67) is noted in almost all high-grade urothelial lesions. However, the aetiological role or, conversely, the absence of causative effect of high-risk human papillomaviruses (hr-HPVs) has not been documented. The purpose of this study is to evaluate HPV DNA in p16/Ki-67-positive, high-grade urothelial tumour cells. METHODS Fifty-seven urine samples collected from 50 patients, including 55 histologically proven high-grade proliferations and two cases with clinical evidence of malignancy, were analysed for p16/Ki-67. Immunolabelling was performed in destained Papanicolaou-stained slides after ThinPrep(®) processing. HPV genotyping was performed by polymerase chain reaction (PCR) using a DNA microarray for 35 HPV types. Confirmation of the presence (or absence) of HPV in tissue samples was verified using a reasoned approach combining PCR and in situ hybridization (ISH) for hr-HPVs. RESULTS Co-expression of p16/Ki-67 was noted in 43 of 57 (75.4%) cases. In these, hr-HPVs 16, 31 and 70, and low risk HPV 84, were detected in the urine in four patients (8%). Upregulation of p16INK4a protein was confirmed on bladder biopsy or transurethral resection specimens, but PCR and ISH for hr-HPVs were both negative on the tissue sections. CONCLUSION Our results show a low prevalence of HPV infection in the urinary tract of patients with p16/Ki-67-positive urothelial malignancy. The study confirms that the deregulated cell cycle, as demonstrated by p16/Ki-67 dual labelling, is independent of the oncogenic action of hr-HPVs in high-grade urothelial proliferations.
Collapse
Affiliation(s)
- A-S Advenier
- Centre de Pathologie Est, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France; Université Claude Bernard Lyon 1, Lyon, France
| | | | | | | | | | | | | |
Collapse
|
9
|
Piaton E, Decaussin-Petrucci M, Mege-Lechevallier F, Advenier AS, Devonec M, Ruffion A. Diagnostic terminology for urinary cytology reports including the new subcategories ‘atypical urothelial cells of undetermined significance’ (AUC-US) and ‘cannot exclude high grade’ (AUC-H). Cytopathology 2013; 25:27-38. [DOI: 10.1111/cyt.12050] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/07/2013] [Indexed: 12/31/2022]
Affiliation(s)
- E. Piaton
- Hospices Civils de Lyon; Centre de Pathologie Est; Hôpital Femme-Mère-Enfant; Bron France
- Université Claude Bernard Lyon 1; Lyon France
| | - M. Decaussin-Petrucci
- Université Claude Bernard Lyon 1; Lyon France
- Centre de Pathologie Sud; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - F. Mege-Lechevallier
- Université Claude Bernard Lyon 1; Lyon France
- Service d'Anatomie et Cytologie Pathologiques; Hôpital Edouard Herriot; Lyon France
| | - A.-S. Advenier
- Hospices Civils de Lyon; Centre de Pathologie Est; Hôpital Femme-Mère-Enfant; Bron France
| | - M. Devonec
- Université Claude Bernard Lyon 1; Lyon France
- Service d'Urologie; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - A. Ruffion
- Université Claude Bernard Lyon 1; Lyon France
- Service d'Urologie; Centre Hospitalier Lyon Sud; Pierre Bénite France
| |
Collapse
|
10
|
Nechifor-Boilă IA, Bancu S, Buruian M, Charlot M, Decaussin-Petrucci M, Krauth JS, Nechifor-Boilă AC, Borda A. Diffusion weighted imaging with background body signal suppression / T2 image fusion in magnetic resonance mammography for breast cancer diagnosis. Chirurgia (Bucur) 2013; 108:199-205. [PMID: 23618570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/01/2013] [Indexed: 06/02/2023]
Abstract
INTRODUCTION Dynamic Contrast-Enhanced Magnetic Resonance Mammography (DCE-MRM) represents the most sensitive examination for breast cancer (BC) diagnosis. However literature data reports very inhomogeneous specificity. The aim of our study was to evaluate the clinical efficiency of a new MRM technique - diffusion weighted imaging with background body signal suppression T2 image fusion in BC diagnosis, compared to DCE-MRM. METHODS We retrospectively analyzed 50 consecutive DCE-MRM examinations with DWIBS sequence from the archives of the Department of Radiology, Lyon Sud Hospital, (02.2010- 02.2011), summing up to 64 breast lesions. Fusions were created using the Osirix software from the DWIBS images (b=1000 s mm2) and their T2 correspondents. Interpretation was performed using an adapted BI-RADS system. The final histopathological examination or a minimum 6-months follow-up served as gold standard. RESULTS Out of the 64 examined breast lesions, 35(54.7%) were classified as malignant by DCE-MRM and 24(37.5%) cases by DWIBS T2, respectively. Thus the DWIBS T2 fusion had a Sensitivity of 62.5%(95%CI:35.4-84.8) and a Specificity of 70.8%(95%CI:55.9-83.3) while DCE-MRM had a higher Sensitivity: 87.5%(95%CI:61.6-98.4) but a lower Specificity: 56.2%(95%CI:41.1-70.5). CONCLUSION DWIBS T2 fusion is an innovative MRM technique, with a specificity superior to DCE-MRM, showing a large potential for improving the clinical efficiency of classical MRM.
Collapse
Affiliation(s)
- I A Nechifor-Boilă
- Târgu Mureş University of Medicine and Pharmacy, Department of Radiology and Medical Imaging, Târgu Mureş, Romania.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Arvin-berod A, Fiard G, Pasquier D, Decaussin-Petrucci M, Arnouil N, Thuillier C, Boillot B, Terrier N, Descotes JL, Paparel P, Rambeaud JJ, Ruffion A, Long JA. Performance de la biopsie endoscopique d’une tumeur de la voie excrétrice supérieure pour la détermination du stade et du grade. Prog Urol 2012. [DOI: 10.1016/j.purol.2012.08.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
12
|
Piaton E, Advenier AS, Carré C, Decaussin-Petrucci M, Mege-Lechevallier F, Ruffion A. p16INK4a/Ki-67 dual labelling as a marker for the presence of high-grade cancer cells or disease progression in urinary cytopathology. Cytopathology 2012; 24:327-34. [DOI: 10.1111/j.1365-2303.2012.01008.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
13
|
Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, Caleo A, Migliaccio I, Decaussin-Petrucci M, Santoro M, Palombini L, Fusco A. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer 2005; 93:464-71. [PMID: 16106252 PMCID: PMC2361574 DOI: 10.1038/sj.bjc.6602721] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
The hybridisation of an Affymetrix HG_U95Av2 oligonucleotide array with RNAs extracted from six human thyroid carcinoma cell lines and a normal human thyroid primary cell culture led us to the identification of the UbcH10 gene that was upregulated by 150-fold in all of the carcinoma cell lines in comparison to the primary culture cells of human normal thyroid origin. Immunohistochemical studies performed on paraffin-embedded tissue sections showed abundant UbcH10 levels in thyroid anaplastic carcinoma samples, whereas no detectable UbcH10 expression was observed in normal thyroid tissues, in adenomas and goiters. Papillary and follicular carcinomas were only weakly positive. These results were further confirmed by RT-PCR and Western blot analyses. The block of UbcH10 protein synthesis induced by RNA interference significantly reduced the growth rate of thyroid carcinoma cell lines. Taken together, these results would indicate that UbcH10 overexpression is involved in thyroid cell proliferation, and may represent a marker of thyroid anaplastic carcinomas.
Collapse
Affiliation(s)
- P Pallante
- Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy
| | - M T Berlingieri
- Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy
| | - G Troncone
- Dipartimento di Anatomia Patologica e Citopatologia, Facoltà di Medicina e Chirurgia di Napoli, Università di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy
| | - M Kruhoffer
- Department of Clinical Biochemistry, Aarhus University Hospital, Skejby DK 8200 Aarhus N, Denmark
| | - T F Orntoft
- Department of Clinical Biochemistry, Aarhus University Hospital, Skejby DK 8200 Aarhus N, Denmark
| | - G Viglietto
- Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy
| | - A Caleo
- Dipartimento di Anatomia Patologica e Citopatologia, Facoltà di Medicina e Chirurgia di Napoli, Università di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy
| | - I Migliaccio
- Dipartimento di Anatomia Patologica e Citopatologia, Facoltà di Medicina e Chirurgia di Napoli, Università di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy
| | - M Decaussin-Petrucci
- Service d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - M Santoro
- Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy
| | - L Palombini
- Dipartimento di Anatomia Patologica e Citopatologia, Facoltà di Medicina e Chirurgia di Napoli, Università di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy
| | - A Fusco
- Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy
- NOGEC (Naples Oncogenomic Center)-CEINGE, Biotecnologie Avanzate, via Comunale Margherita, 80131 Naples, Italy
- Dipartimento di Biologia e Patologia Cellulare e Molecolare, Facoltà di Medicina e Chirurgia di Napoli and, NOGEC (Naples Oncogenomic Center)-CEINGE, Biotecnologie Avanzate, via Pansini 5, 80131 Napoli, Italy. E-mail:
| |
Collapse
|